A new formulation of epoprostenol containing arginine and sucrose excipients for treatment of pulmonary arterial hypertension (PAH) was developed to have greater stability at room temperature than existing formulations.

In this open-label, Phase 3b study, the authors compared the safety, efficacy, and treatment satisfaction of switching to the new formulation of epoprostenol in eight Japanese patients with PAH.

Regarding treatment satisfaction, there was a significant improvement in convenience, which is demonstrated in the score of the domain increased from 51.40 ± 10.19 at baseline to 58.33 ± 12.96 at week 12 (P < 0.05).

Switching to the new formulation of epoprostenol was associated with improved treatment satisfaction, particularly convenience, without unexpected adverse effects or deteriorations in pulmonary hemodynamic factors.

This summary slide represents the opinions of the authors, and not necessarily the opinions of the publisher or editorial board. Sponsorship for this study and summary slide was funded by Actelion Pharmaceuticals Japan Ltd. Medical writing assistance for this study and summary slide was provided by Nicholas D. Smith, PhD., an employee of Edanz, which was funded by Actelion Pharmaceuticals Japan Ltd.